|
業務類別
|
-- |
|
業務概覽
|
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the United States. |
| 公司地址
| 218 Xinghu Street, Suite 202, Building A3, Suzhou Industrial Park, Suzhou, CHN, 215123 |
| 電話號碼
| +86 51265790025 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.harbourbiomed.com |
| 員工數量
| 177 |
| Dr. Yiping Rong |
Director and Chief Scientific Officer |
-- |
22/04/2025 |
| Dr. Jingsong Wang |
Chairman of the Board and Chief Executive Officer |
-- |
22/04/2025 |
|
|
| Dr. Yiping Rong |
Director and Chief Scientific Officer |
22/04/2025 |
| Dr. Jingsong Wang |
Chairman of the Board and Chief Executive Officer |
22/04/2025 |
| Dr. Robert Irwin Kamen |
Independent Director |
22/04/2025 |
| Mr. Albert R. Collinson |
Independent Director |
22/04/2025 |
| Ms. Weiwei Chen |
Independent Director |
22/04/2025 |
| Dr. Xiaoping Ye |
Independent Director |
22/04/2025 |
|
|
|
|
